Table 4. Outcomes at follow-up for study population.
| Characteristic | All types (n=200) | Type I Cr.GN
(anti-GBM) (n=31) |
Type II Cr.GN
(immune complex) (n=93) |
Type III Cr.GN
(pauci-immune) (n=76) |
P value |
|---|---|---|---|---|---|
| Follow-up (months, mean±SD) | 9.4±15.5 | 4.6±8.3 | 10±15.1 | 10.6±17.8 | 0.17 |
| Serum creatinine at last follow-up
(mg/dL, mean±SD, n) |
3.7±3.5 (95) | 7.2±5.8 (6) | 3.4±3.3 (49) | 3.5±3.1 (40) |
0.03
@,
0.04 # |
| eGFR (CKD-EPI) at last follow-up
(ml/min/1.73m 2, median (IQR), n) |
27.5 (11.3-54.5) (95) | 11 (4-34) (6) | 32 (42.3-33.8) (49) | 24.5 (14-43) (40) | 0.07 |
| eGFR change from baseline (n/N (%))
eGFR loss & no change in CKD stage eGFR loss & change in CKD stage eGFR gain & no change in CKD stage eGFR gain & change in CKD stage |
11/105 (11.6)
10/105 (10.5) 24/105 (25.3) 50/105 (52.6) |
3/6 (50)
0 1/6 (16.7) 2/6 (33.3) |
3/49 (6.1)
6/49 (12.2) 13/49 (26.5) 27/49 (55.1) |
5/40 (12.5)
4/40 (10) 10/40 (13.2) 21/40 (52.5) |
|
| ESKD | 89 (44.5) | 24 (77.4) | 28 (30.1) | 38 (50) | <0.001 |
| Hemodialysis (n (%)) | 87 (43.5) | 24 (77.4) | 28 (30.1) | 35 (46) | <0.001 |
| Infections (n (%)) | 34 (17) | 5 (16.1) | 19 (20.4) | 10 (13.2) | 0.45 |
| Death | 9 (4.5) | 0 | 4 (4.3) | 5 (6.6) | 0.17 |
Abbreviations: eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula); ESKD, end stage kidney disease; Cr.GN, crescentic glomerulonephritis; GBM, glomerular basement membrane.
P value is significant at <0.05 between @ Type 1 and Type III, #Type II and Type III, $Type 1 and Type II analyzed by One-way ANOVA with Bonferroni correction.